Literature DB >> 22851468

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

Rodney P E Pollard, Wayel H Abdulahad, Arjan Vissink, Nishath Hamza, Johannes G M Burgerhof, Jiska M Meijer, Annie Visser, Minke G Huitema, Fred K L Spijkervet, Cees G M Kallenberg, Hendrika Bootsma, Frans G M Kroese.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22851468     DOI： 10.1136/annrheumdis-2012-202071

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  23 in total

Review 1.  Lupus nephritis: the evolving role of novel therapeutics.

Authors:  Brad H Rovin; Samir V Parikh
Journal:  Am J Kidney Dis       Date:  2014-01-07       Impact factor: 8.860

2.  Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.

Authors:  Jagdeep Singh; Ranjana Walker Minz; Biman Saikia; Ritambhra Nada; Aman Sharma; Saket Jha; Shashi Anand; Manish Rathi; Sanjay D'Cruz
Journal:  Clin Exp Med       Date:  2022-10-11       Impact factor: 5.057

Review 3.  B-cell survival factors in autoimmune rheumatic disorders.

Authors:  Sandra A Morais; Andreia Vilas-Boas; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

Review 4.  Current and future therapies for primary Sjögren syndrome.

Authors:  Raphaèle Seror; Gaetane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

Review 5.  Current and Emerging Therapies for Lupus Nephritis.

Authors:  Samir V Parikh; Brad H Rovin
Journal:  J Am Soc Nephrol       Date:  2016-06-09       Impact factor: 10.121

Review 6.  B cells in the pathogenesis of primary Sjögren syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

Review 7.  Experimental modeling of desensitization: What have we learned about preventing AMR?

Authors:  Jean Kwun; Stuart Knechtle
Journal:  Am J Transplant       Date:  2020-06       Impact factor: 8.086

Review 8.  Induction Therapy for Lupus Nephritis: the Highlights.

Authors:  Isabelle Ayoub; Jessica Nelson; Brad H Rovin
Journal:  Curr Rheumatol Rep       Date:  2018-08-14       Impact factor: 4.592

9.  Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection.

Authors:  Kenna R Degner; Nancy A Wilson; Shannon R Reese; Sandesh Parajuli; Fahad Aziz; Neetika Garg; Maha Mohamed; Tripti Singh; Didier A Mandelbrot; Sarah E Panzer; Robert R Redfield; Kristin Van Hyfte; Weixiong Zhong; Luis G Hidalgo; Arjang Djamali
Journal:  Kidney360       Date:  2020-05-28

10.  BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice.

Authors:  Tin Kyaw; Peng Cui; Christopher Tay; Peter Kanellakis; Hamid Hosseini; Edgar Liu; Antonius G Rolink; Peter Tipping; Alex Bobik; Ban-Hock Toh
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.